| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
REDWOOD CITY, Calif.—Codexis Inc., a protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have signed an agreement to advance a lead candidate discovered through a strategic collaboration agreement (SCA) into preclinical development and early clinical studies. The SCA, signed in 2017, was an agreement to co-discover new enzyme therapy candidates for Nestlé Health Science’s nutritional therapies portfolio.
 
The companies’ new agreement will advance the development of CDX-7108, the lead candidate for a potential treatment of a gastrointestinal (GI) disorder. In parallel, the original SCA will be extended through the end of 2021 to support the discovery of therapeutic candidates for additional disorders.
 
“Our new and extended agreements with Codexis are a demonstration of the progress of the biotherapeutic pipeline as a result of our partnership, building on the previously established clinical success with CDX-6114 targeting phenylketonuria,” said Greg Behar, CEO of Nestlé Health Science. “The CDX-7108 program is the first project performed under the SCA, and in less than two years from conceptualization, we have created an orally administrable enzyme candidate that meets our target criteria for advancement.”
 
Added John Nicols, Codexis’ president and CEO: “This partnership was initiated to leverage and extend the application of the CodeEvolver protein engineering platform and to create novel enzymes that will further fuel our biotherapeutics pipeline. Two years into the collaboration, we are excited to advance our first candidate into formal preclinical development. In parallel, it is equally satisfying to see Nestlé Health Science endorse the wider possibilities of creating value with our CodeEvolver technology by continuing our productive collaboration on other therapeutic concepts in this extended SCA chapter.”
 
Under the development agreements, Codexis and Nestlé Health Science will retain joint ownership over the rights to CDX-7108, as they move this therapeutic enzyme candidate into preclinical and clinical development.

Related Topics

Published In

Volume 16 - Issue 2 | February 2020

February 2020

February 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue